NCX 1022
Alternative Names: NCX-1022; Nitric oxide-donating derivative of hydrocortisone - NicOx; NO-hydrocortisoneLatest Information Update: 24 Oct 2021
At a glance
- Originator NicOx
- Developer Ferrer; NicOx
- Class Antipsoriatics; Glucocorticoids; Pregnenediones
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis; Seborrhoeic dermatitis
Most Recent Events
- 10 Oct 2007 No development reported - Phase-I for Psoriasis in France (Topical)
- 10 Oct 2007 No development reported - Phase-II for Seborrhoeic dermatitis in France (Topical)
- 15 Sep 2005 NicOx expands its existing collaboration with Ferrer Grupo International for the research, development and marketing of nitric oxide-donating corticosteroids for dermatological indications, including NCX 1022